Features | Partner Sites | Information | LinkXpress
Sign In
Fluke Biomedical
Schiller
Ampronix

Protection Device Minimizes Brain Damage in Cardiovascular Procedures

By HospiMedica International staff writers
Posted on 02 Oct 2013
Image: The TriGuard Cerebral Protection Device (Photo courtesy of Keystone Heart).
Image: The TriGuard Cerebral Protection Device (Photo courtesy of Keystone Heart).
An innovative cerebral protection device (CPD) reduces the volume of new brain lesions, especially during protected transcatheter aortic valve replacement (TAVR).

The TriGuard CPD is a Nitinol mesh embolic debris deflection device designed to cover all three aortic cerebral branches to minimize the risk of brain damage during cardiovascular (CV) procedures, and accommodates most anatomical variations of the aortic arch. The Nitinol frame and mesh are designed to be flexible and atraumatic, yet robust and sturdy, thus providing simple placement and retrieval.

The device is placed via one of two femoral artery access ports typically used in TAVR, eliminating the need for a third puncture site, and deploys rapidly, self-positioning through a 3-mm catheter. Studies have shown that compared with historical data on unprotected TAVR procedures, use of the TriGuard CPD decreased maximum total lesion volume by 95%, while average total lesion volume was 57% smaller, when compared with historical references. The TriGuard Cerebral Protection Device is a product of Keystone Heart (Caesarea, Israel), and has received the European community CE marking of approval.

“Cerebral function is the essence of quality of life. Its preservation throughout medical procedures is a key component to procedural success and patient care. TriGuard is the most sophisticated cerebral embolic protection device currently available,” said Andreas Baumbach, MD, consultant cardiologist at University Hospitals Bristol (United Kingdom). “The device has the potential to become a routine preventive measure in TAVR and other cardiovascular procedures associated with embolic lesions.”

Cerebral emboli are commonly associated with left-sided cardiac procedures. During CV procedures, debris from the aortic valve, ascending aorta, and other sources may embolize and cause cerebral infarction. Cerebral damage may not be clinically evident after CV procedures and can take months or years for symptoms to manifest, often as devastating stroke, dementia, and cognitive decline. Embolic brain lesions can be objectively and consistently detected by diffusion-weighted magnetic resonance imaging (DW-MRI).

Related Links:

Keystone Heart
University Hospitals Bristol



Bovie Medical
MinXray
Centurion Service

Channels

Critical Care

view channel
Image: The Trellis peripheral infusion system (Photo courtesy of Covidien).

Thrombolytic Drug Delivery Device Dissolves Blood Clots

A redesigned peripheral infusion system enables focused treatment of blood clots to avoid potential post-thrombotic syndrome (PTS). The updated Trellis peripheral infusion system is a pharmacomechanical... Read more

Women's Health

view channel
Image: A prototype contraceptive implant (Photo courtesy of MicroCHIPS).

Contraceptive Implant Hails New Era of Birth Control

A fingernail-sized implant holds enough 30-microgram daily doses of levonorgestrel to provide contraception for 16 years. Developed by MicroCHIPS (Lexington, MA, USA), a MIT (Cambridge, MA, USA) startup,... Read more

Health IT

view channel

Wikipedia Dominates Internet Drug Information

Wikipedia, along with Google and WebMD, is where more than half of all Americans turn to for health information on prescription drugs. Researchers at the Blackstone Group (London, United Kingdom), Harvard Medical School (Boston, MA, USA), and other institutions selected new drug-safety communications related to prescription... Read more

Business

view channel

Spectranetics Completes Acquisition of AngioScore

Spectranetics (Colorado Springs, CO, USA) has completed the acquisition of AngioScore (Fremont, CA, USA), a leading developer, manufacturer, and marketer of cardiovascular specialty balloons. The transaction, for USD 230 million in cash and contingent commercial and regulatory milestone payments, will combine differentiated,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.